AngioDynamics, Inc. (NASDAQ:ANGO) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 326,820 shares of the medical instruments supplier’s stock after acquiring an additional 11,599 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.80% of AngioDynamics worth $2,543,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Quarry LP lifted its holdings in AngioDynamics by 75.1% in the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 2,594 shares in the last quarter. CWM LLC lifted its holdings in AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares in the last quarter. Mackenzie Financial Corp acquired a new position in AngioDynamics in the 2nd quarter worth $80,000. Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics in the 3rd quarter worth $86,000. Finally, AE Wealth Management LLC acquired a new position in AngioDynamics in the 2nd quarter worth $87,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Analyst Upgrades and Downgrades

ANGO has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group cut their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Price Performance

NASDAQ ANGO opened at $9.00 on Monday. The firm has a market capitalization of $365.71 million, a price-to-earnings ratio of -1.48 and a beta of 0.68. The company’s fifty day moving average is $7.02 and its two-hundred day moving average is $6.95. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $9.42.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. During the same period last year, the firm earned ($0.12) EPS. The firm’s revenue for the quarter was down 14.2% compared to the same quarter last year. As a group, sell-side analysts expect that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction dated Monday, October 7th. The stock was bought at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the transaction, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This represents a 3.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders purchased 22,568 shares of company stock valued at $135,847. Insiders own 5.40% of the company’s stock.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.